These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25251069)

  • 1. Current approaches for the discovery of drugs that deter substance and drug abuse.
    Yasgar A; Simeonov A
    Expert Opin Drug Discov; 2014 Nov; 9(11):1319-31. PubMed ID: 25251069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in the use of zebrafish for novel cardiac drug discovery.
    Keßler M; Rottbauer W; Just S
    Expert Opin Drug Discov; 2015; 10(11):1231-41. PubMed ID: 26294375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D in vitro tissue models and their potential for drug screening.
    Kimlin L; Kassis J; Virador V
    Expert Opin Drug Discov; 2013 Dec; 8(12):1455-66. PubMed ID: 24144315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sigma-1 receptors: potential targets for the treatment of substance abuse.
    Robson MJ; Noorbakhsh B; Seminerio MJ; Matsumoto RR
    Curr Pharm Des; 2012; 18(7):902-19. PubMed ID: 22288407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where do we stand in the field of anti-abuse drug discovery?
    Tzschentke TM
    Expert Opin Drug Discov; 2014 Nov; 9(11):1255-8. PubMed ID: 25162980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening methods for influenza antiviral drug discovery.
    Atkins C; Evans CW; White EL; Noah JW
    Expert Opin Drug Discov; 2012 May; 7(5):429-38. PubMed ID: 22435452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
    Corti S; Faravelli I; Cardano M; Conti L
    Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of neuroproteomics in drug abuse research.
    Lull ME; Freeman WM; VanGuilder HD; Vrana KE
    Drug Alcohol Depend; 2010 Feb; 107(1):11-22. PubMed ID: 19926406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?
    Jhoti H; Rees S; Solari R
    Expert Opin Drug Discov; 2013 Dec; 8(12):1449-53. PubMed ID: 24206191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
    Janero DR
    Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models.
    Martinez NJ; Titus SA; Wagner AK; Simeonov A
    Expert Opin Drug Discov; 2015 Dec; 10(12):1347-61. PubMed ID: 26394277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the neurobiology, assessment, and treatment of substances of abuse and dependence: a guide for the critical care nurse.
    Genung V
    Crit Care Nurs Clin North Am; 2012 Mar; 24(1):117-30. PubMed ID: 22405717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting GABAB receptors for anti-abuse drug discovery.
    Phillips TJ; Reed C
    Expert Opin Drug Discov; 2014 Nov; 9(11):1307-17. PubMed ID: 25195620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GABAB receptors as a therapeutic strategy in substance use disorders: focus on positive allosteric modulators.
    Filip M; Frankowska M; Sadakierska-Chudy A; Suder A; Szumiec L; Mierzejewski P; Bienkowski P; Przegaliński E; Cryan JF
    Neuropharmacology; 2015 Jan; 88():36-47. PubMed ID: 24971600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Training the next generation of providers in addiction medicine.
    Rasyidi E; Wilkins JN; Danovitch I
    Psychiatr Clin North Am; 2012 Jun; 35(2):461-80. PubMed ID: 22640766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Abuse Nanotechnology: Opportunities and Challenges.
    Mahmoudi M; Pakpour S; Perry G
    ACS Chem Neurosci; 2018 Oct; 9(10):2288-2298. PubMed ID: 29851334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.
    Janero DR
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids.
    Renner H; Grabos M; Becker KJ; Kagermeier TE; Wu J; Otto M; Peischard S; Zeuschner D; TsyTsyura Y; Disse P; Klingauf J; Leidel SA; Seebohm G; Schöler HR; Bruder JM
    Elife; 2020 Nov; 9():. PubMed ID: 33138918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scaling Up Research on Drug Abuse and Addiction Through Social Media Big Data.
    Kim SJ; Marsch LA; Hancock JT; Das AK
    J Med Internet Res; 2017 Oct; 19(10):e353. PubMed ID: 29089287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.